MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia Jan 12, 2022
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus Nov 24, 2021
PsyBio Therapeutics Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio Aug 4, 2021
PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation Jul 21, 2021
Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology Jul 6, 2021
